- Home
- IONS vs COTY Comparison
IONS vs COTY Comparison
Compare IONS & COTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- COTY
- Stock Information
- Founded
- IONS 1989
- COTY 1904
- Country
- IONS United States
- COTY United States
- Employees
- IONS N/A
- COTY N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- COTY Package Goods/Cosmetics
- Sector
- IONS Health Care
- COTY Consumer Discretionary
- Exchange
- IONS Nasdaq
- COTY Nasdaq
- Market Cap
- IONS 5.9B
- COTY 5.8B
- IPO Year
- IONS 1991
- COTY 2013
- Fundamental
- Price
- IONS $37.41
- COTY $4.78
- Analyst Decision
- IONS Buy
- COTY Buy
- Analyst Count
- IONS 18
- COTY 15
- Target Price
- IONS $57.59
- COTY $7.43
- AVG Volume (30 Days)
- IONS 1.5M
- COTY 9.3M
- Earning Date
- IONS 07-31-2025
- COTY 08-19-2025
- Dividend Yield
- IONS N/A
- COTY N/A
- EPS Growth
- IONS N/A
- COTY N/A
- EPS
- IONS N/A
- COTY N/A
- Revenue
- IONS $717,253,000.00
- COTY $6,003,900,000.00
- Revenue This Year
- IONS $7.98
- COTY N/A
- Revenue Next Year
- IONS $16.09
- COTY $1.19
- P/E Ratio
- IONS N/A
- COTY N/A
- Revenue Growth
- IONS N/A
- COTY N/A
- 52 Week Low
- IONS $23.95
- COTY $4.46
- 52 Week High
- IONS $52.34
- COTY $10.54
- Technical
- Relative Strength Index (RSI)
- IONS 68.61
- COTY 44.20
- Support Level
- IONS $34.78
- COTY $4.73
- Resistance Level
- IONS $37.54
- COTY $5.34
- Average True Range (ATR)
- IONS 1.06
- COTY 0.20
- MACD
- IONS 0.07
- COTY -0.01
- Stochastic Oscillator
- IONS 95.44
- COTY 7.38
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About COTY Coty Inc.
Coty is a global beauty maker that focuses on fragrance (59% of sales) and color cosmetics (28%), with limited exposure to skincare (5%) and body care (8%). For the fragrance business, Coty licenses luxury and high-end brands including Gucci, Burberry, Hugo Boss, Davidoff, and Calvin Klein, while its consumer cosmetics business focuses on acquired mass brands such as CoverGirl, Max Factor, Rimmel, Sally Hansen, and Bourjois. It also collaborates with social media celebrities Kim Kardashian and Kylie Jenner to launch makeup products bearing their names. By region, Coty generates close to 44% of sales from Europe, 42% from the Americas, and 14% from Asia-Pacific. German investment firm JAB is a controlling shareholder, with a 53% stake.